‍

Blake, Wm. The First Book of Urizen, object 21. 1794.

‍

CEOs of everything from snack food to knee implants are growing increasingly concerned about the weight-loss drug Ozempic, contacting the drugmaker themselves to receive reassurance that their profits will not be hurt.

The CEO of Novo Nordisk, the company behind the drug, said during an interview: “A couple of CEOs from, say, food companies have been calling me.” He declined to name names, saying questions had centered on how the drugs work and how fast they would roll out. “They are scared about it.”

Some companies, like Walmart, have publicly voiced concerns. The retail corporation said last October that Ozempic is making customers purchase less food, citing anonymized data. Chipotle, meanwhile, believes fresh food will still appeal to people who are trying to lose weight.

Sean Connolly, CEO of packaged goods giant Conagra Brands, said the snackmaker has “an entire department of demand scientists” studying changes in consumer behavior every day.

“There’s still so many unknowns regarding the rate of adoption, the impact on food choices,” Hershey’s Co. CEO said on a call last year. “We’re doing more work constantly to understand those future potential impacts on our categories.”